AbbVie Inc (ABBV)vsAirsculpt Technologies Inc (AIRS)
ABBV
AbbVie Inc
$294.89
+1.41%
HEALTHCARE · Cap: $521.11B
AIRS
Airsculpt Technologies Inc
$1.73
+3.59%
HEALTHCARE · Cap: $124.72M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 43698% more annual revenue ($66.01B vs $150.72M). ABBV leads profitability with a 15.7% profit margin vs -7.8%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
AIRS
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$294.89
$138.05 premium
Margin of Safety
+32.9%
Fair Value
$3.16
Current Price
$1.73
$1.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 200.0% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -11.2% — below average capital efficiency
Revenue declined 2.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : AIRS
The strongest argument for AIRS centers on Price/Book, EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : AIRS
The primary concerns for AIRS are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while AIRS is a turnaround play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.33 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 41/100), backed by strong 15.7% margins and 10.3% revenue growth. AIRS offers better value entry with a 32.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its service offerings, driving robust growth and long-term value for its investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?